Particularly, checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) as monotherapy or in combination with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors have significantly improved survival for a sub-group of MM patients [1,2]. Here, PDCD1 is linked to Miyoshi myopathy.